Difference between revisions of "Example orders for Cetuximab (Erbitux) in colon cancer"
Jump to navigation
Jump to search
m (Text replace - "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' {{TOC limit|limit=3}}" to "'''Use of this site is subject to you read) |
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
||
| (18 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].''' | + | <!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''--> |
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | ||
| Line 7: | Line 7: | ||
==Cetuximab (Erbitux)== | ==Cetuximab (Erbitux)== | ||
| − | Original references may be found at [[Colon_cancer# | + | Original references may be found at [[Colon_cancer#Cetuximab_monotherapy|Cetuximab (Erbitux)]] |
===Example regimen #1=== | ===Example regimen #1=== | ||
For cycle 1: | For cycle 1: | ||
| − | *[[Cetuximab (Erbitux)]] 400 mg/ | + | *[[Cetuximab (Erbitux)]] 400 mg/m<sup>2</sup> IV over 2 hours on day 1 |
**Use non-DEHP/paclitaxel tubing. | **Use non-DEHP/paclitaxel tubing. | ||
| − | *[[Cetuximab (Erbitux)]] 250 mg/ | + | *[[Cetuximab (Erbitux)]] 250 mg/m<sup>2</sup> IV over 60 minutes on days 8, 15, 22 |
**Use non-DEHP/paclitaxel tubing. | **Use non-DEHP/paclitaxel tubing. | ||
'''28-day cycle''' | '''28-day cycle''' | ||
| − | Supportive | + | ====Supportive therapy==== |
| − | *Acetaminophen (Tylenol) 650 mg PO 30 minutes prior to cetuximab | + | *Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to cetuximab |
*Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab | *Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab | ||
Hydration: | Hydration: | ||
| − | *500 ml NS at KVO rate as running IV for chemotherapy infusion. | + | *500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS. |
Monitoring: | Monitoring: | ||
| − | *Hold if ANC | + | *Hold if ANC less than 1000 or platelets less than 100 and notify physician. |
For cycle 2 and later: | For cycle 2 and later: | ||
| − | *[[Cetuximab (Erbitux)]] 250 mg/ | + | *[[Cetuximab (Erbitux)]] 250 mg/m<sup>2</sup> IV over 60 minutes on days 1, 8, 15, 22 |
**Use non-DEHP/paclitaxel tubing. | **Use non-DEHP/paclitaxel tubing. | ||
'''28-day cycles''' | '''28-day cycles''' | ||
| − | Supportive | + | ====Supportive therapy==== |
| − | *Acetaminophen (Tylenol) 650 mg PO 30 minutes prior to cetuximab | + | *Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to cetuximab |
*Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab | *Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab | ||
Hydration: | Hydration: | ||
| − | *500 ml NS at KVO rate as running IV for chemotherapy infusion. | + | *500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS. |
Monitoring: | Monitoring: | ||
| − | *Hold if ANC | + | *Hold if ANC less than 1000 or platelets less than 100 and notify physician. |
'''Comments:''' | '''Comments:''' | ||
Latest revision as of 02:03, 1 June 2023
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
Cetuximab (Erbitux)
Original references may be found at Cetuximab (Erbitux)
Example regimen #1
For cycle 1:
- Cetuximab (Erbitux) 400 mg/m2 IV over 2 hours on day 1
- Use non-DEHP/paclitaxel tubing.
- Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 8, 15, 22
- Use non-DEHP/paclitaxel tubing.
28-day cycle
Supportive therapy
- Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to cetuximab
- Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab
Hydration:
- 500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
- Hold if ANC less than 1000 or platelets less than 100 and notify physician.
For cycle 2 and later:
- Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 1, 8, 15, 22
- Use non-DEHP/paclitaxel tubing.
28-day cycles
Supportive therapy
- Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to cetuximab
- Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab
Hydration:
- 500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
- Hold if ANC less than 1000 or platelets less than 100 and notify physician.
Comments:
- My institution uses 28-day cycles for Cetuximab (Erbitux) regimens.